Phase Ib Loncastuximab Tesirine (anti-CD19 ADC) and Roflumilast (PDE4 inhibitor) in High-Risk DLBCL

This Phase Ib single-arm trial evaluates a combination of Loncastuximab Tesirine, Roflumilast, and standard R-CHOP in newly diagnosed high-risk diffuse large B-cell lymphoma. The study, led by The University of Texas Health Science Center at San Antonio, will assess safety, tolerability, and tumor response.